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Hyaluronan is a linear glycosaminoglycan, which is ubiquitiously
distributed in the extracellular matrix and regulates several normal
physiological functions such as cell migration, growth, differentia-
tion and cell adhesion (Laurent and Fraser, 1992; Laurent et al,
1995; Knudson, 1998). It is synthesized at the inner leaflet of the
plasma membrane by hyaluronan synthases (HAS1, HAS2 and
HAS3; Itano and Kimata, 1996; Shyjan et al, 1996; Spicer et al,
1996, 1997; Watanabe and Yamaguchi, 1996); each HAS isoform
is capable of synthesizing hyaluronan, exhibits a cell specific
expression pattern, and possesses distinct enzymic properties
(Brinck and Heldin, 1999; Itano et al, 1999b; Jacobson et al,
2000). Among the three HAS isoforms tested it appears that
mainly HAS2 expression is affected in response to external stimuli
(Brick and Heldin, 1999; Li et al, 2000; Jacobson et al, 2000). 
Several studies have shown that hyaluronan synthesis is often
increased in certain human tumours and occur predominantly
within the tumour-adjacent connective tissue (Bertrand et al, 1992;
Auvinen et al, 1997; Ropponen et al, 1998). The hyaluronan in
tumours is either produced by tumour cells themselves (Delpech
et al, 1997), or by adjacent noncancerous stromal cells (Asplund
et al, 1993). Hyaluronan overproduction leads to remodelling of
the extracellular matrix surrounding tumour cells and correlates
with their invasive and metastatic behaviour (Kimata et al, 1983;
Zhang et al, 1995). 
Mesothelioma is a malignant tumour of the pleura and peri-
toneum which is linked to asbestos exposure. However, other
factors such as chemical carcinogens, chronic inflammation and
viral SV 40 exposure may contribute to the development of this
neoplasia (Bielefeldt-Ohmann et al, 1996). Mesotheliomas do not
exhibit abnormalities in the common target genes ras and p53, but
loss of p16INK4a expression is commonly observed in these
tumours (Metcalf et al, 1992; Frizelle et al, 1998). Malignant
mesothelioma is characterized by a highly invasive behaviour
(Scarpa et al, 1999). A number of mesotheliomas produce
hyaluronan (Klominek et al, 1989), whereas others do not produce
hyaluronan but release growth factors which stimulate surrounding
normal cells to synthesize hyaluronan (Asplund et al, 1993). 
In this study, we investigated the relationship between cellular
hyaluronan production and the malignant phenotype of meso-
thelioma cells. We transfected the non-hyaluronan producing
mesothelioma cell line Mero-25 (Asplund et al, 1993) with cDNA
for HAS2, and demonstrated that hyaluronan production by Mero-
25 cells induced differentiation of the cells to a more fibroblastic
phenotype. Furthermore, increased hyaluronan synthesis enhanced
cell proliferation, anchorage-independent growth and cell migration. 
MATERIALS AND METHODS 
Materials and cell lines 
Ham’s F-10 medium and fetal calf serum (FCS) were purchased
from Swedish Veterinary Institute (Uppsala, Sweden). Opti-MEM
medium and LipofectAMINE were purchased from Gibco, UK.
G418 sulfate (geneticin) was purchased from Calbiochem, CA.
Vitrogen 100 (purified type I collagen) was purchased from
Collagen Corporation (Palo Alto, CA). pCIneo plasmid containing
open reading frame (ORF) for mouse HAS2 was a generous gift
from Dr Andrew Spicer, California, USA. The human mesothe-
lioma cell line, Mero-25, was kindly provided by Dr M Versnel
(Rotterdam, Netherlands). Streptomyces hyaluronidase was
purchased from Seikagaku Corporation, Japan. [3H]glycosamine
hydrochloride (18.5 Ci mmol–1) was purchased from DuPont NEN
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(Boston, MA). 3H-labelled hyaluronan with a specific activity of
42 × 104 dpm µ g–1, and a molecular weight of 3.85 × 106 was
generously provided by Dr JRE Fraser (Melbourne, Australia).
Hyaluronan of various molecular weights was a kind gift from 
Dr O Wik (Q-Med, Uppsala, Sweden). The human CD44 mAb
against Hermes-3 (mouse IgG2a) was kindly provided by Dr S
Jalkanen (Turku, Finland). Cyclin A, cyclin B, p21 and Cdc2 
p34 monoclonal antibodies were purchased from Santa Cruz
(UK). Secondary peroxidase-conjugated anti-mouse IgG, were
purchased from Amersham Pharmacia Biotech (Sweden). 
Stable transfection of HAS2 cDNA into mesothelioma
cells 
The human mesothelioma cells, Mero-25, were grown in Ham’s 
F-10 medium containing 15% FCS, 4 mM glutamine, 100 IU ml–1
penicillin and 100 µ g ml–1 streptomycin (complete medium).
Subconfluent cultures of Mero-25 cells were transfected with 
2 µ g ml–1 of pCIneo vector containing the open reading frame for
HAS2 (Spicer et al, 1996) using LipofectAMINE according to the
manufacturer’s instructions. Mock-transfected cells, i.e. cells
transfected with the empty pCIneo vector (Promega), were used as
a control. 3 days after transfection, single clones were isolated
with a pipette and seeded on 24-well plates in complete medium
supplemented with 800 µ g ml–1 G418 for selection of stable trans-
fected clones. G418-resistant colonies were examined for HAS2
expression by measuring the hyaluronan content in 24 h condi-
tioned media by using a commercial kit (Pharmacia HA Test,
Uppsala, Sweden). This kit is based on the specificity of a
hyaluronan-binding protein (Tengblad, 1980). 
Determination of hyaluronan synthesized by
mesothelioma transfectants 
The hyaluronan-synthesizing capacity of HAS2-transfectants was
determined by visualization of hyaluronan containing pericellular
coats essentially as descibed previously (Clarris and Fraser, 1968;
Heldin and Pertoft, 1993). Sparsely seeded mock-and HAS2-
transfectant clones (5 × 104 cells/35 mm dish) were incubated for
24 h in complete medium, and were then overlaid with 1 × 107
formalin-fixed erythrocytes. The erythrocytes were then allowed
to settle for 15 min at room temperature and the cells were
observed with an inverted microscope with a phase contrast at
600x magnification with a Nikon camera. The size of the pericel-
lular coat was defined by the ratio between the area excluding
erythrocytes and cell area and was calculated by using NIH image
program. A ratio of the excluded area:cell area equal to 1.0 repre-
sents no detectable coats. 
To determine the molecular mass of hyaluronan molecules
synthesized de novo by mock-transfected cells or cells stably
transfected with cDNA for HAS2, 1 × 105 cells well–1 on a 6-well
plate were grown in 1 ml complete medium supplemented with 5
µ Ci of [3H]glucosamine, a precursor of both hyaluronan and
sulfated glycosaminoglycans. After 24 h, conditioned media from
2 wells were harvested, combined and dialysed for 48 h against 0.1
M sodium acetate buffer, pH 5.5, containing 5 mM EDTA (Mw cut-
off 3500). The dialysate was then divided into 2 equal aliquots.
One aliquot was treated overnight with 10 U ml–1 Streptomyces
hyaluronidase at 37˚C, whereas the other was treated in a similar
way but in the absence of the hyaluronidase. Following enzyme
inactivation by heating, the samples were subjected to gel chro-
matography on a Sephacryl-HR column (1 × 100 cm) composed of
different layers of Sephacryl-HR with different porosities (Lebel
et al, 1988). The column was equilibrated and eluted with 0.25 M
NaCl containing 0.05% chlorbutanol. Fractions of 1 ml were
collected and the radioactivity was measured in a Pharmacia LKB
Wallac scintillation counter. 
Proliferation assay 
Differencies in the proliferative capacity between HAS2- and
mock-transfectants were examined by counting the cell number at
1, 3, 6 and 9 days after subculturing. The relative increase in the
cell number was defined by the ratio between the amount of cells
at different times after subculture and the cell number obtained at 1
day after subculture. 
Cell cycle analysis 
HAS2- or mock-transfected mesothelioma cells (1 × 105 cells/well
in 6-well plates) were cultured in complete medium for 24 h.
Then, the cells were synchronized by culturing in starvation
medium for an additional 48 h. At this time, the starvation medium
was aspirated and fresh medium containing 3% FCS was added.
After 48 h of culturing, cells were washed in PBS, trypsinazed and
pelleted by centrifugation. For flow cytometric analysis, the cell
pellets (1 × 106 cells) were resuspended in 450 µ l stock solution
buffer (3.4 mM trisodium citrate, 0.1% Nonidet P 40, 1.5 mM
spermine tetrahydrochloride and 0.5 mM Tris, pH 7.6) containing
trypsin (15 µ g ml–1). Cells where then subjected to DNA content
analysis and cell cycle kinetics as described by Vindelöv
(Vindelöv et al, 1983) using a Becton Dickinson FACStar plus
flow cytometer. 
Soft agar growth assay 
Mock- and HAS2-transfected mesothelioma cells (1.5 × 105 cells)
were separately suspended in 3 ml F-10 medium containing 15%
FCS prewarmed to 37˚C. Each cell suspension was mixed with
300 µ l of a prewarmed (60 ˚C) 3% agarose/PBS solution and
layered into 3 wells of 6-well plates (1 ml well–1), that were previ-
ously coated with 1 ml of 0.6% agarose in F-10 medium. The
agarose was allowed to solidify at room temperature for 20 min
before 3 ml of complete medium was added to each well. At 4
weeks plating, 10 fields were selected randomly and colonies
larger than 0.5 arbitrary units were counted by a Nikon micro-
scope. The area of the colonies was measured by using a NIH
image program. 
Western blotting 
Cell lysates (1 × 106 cells per 100-mm dish) were solubilized in
ice-cold RIPA buffer (10 mM Tris-HCl, pH 7.4, 0.15 M NaCl, 
1% Triton X-100, 0.1% SDS, 0.65 mM MgSO4 1 mM CaCl2, 
0.5% deoxycholate) containing protease inhibitors (10 turbidity
units ml–1 aprotinin, 1 µ gm l –1 leupeptin, 0.1 mM pefabloc, 1 µ M
pepstatin and 0.25 mg ml–1 DNase I) for 2 h at 4˚C, using a
rocking platform. Lysates were centrifuged at 13 000 rpm for 
15 min at 4˚C and the protein content of the supernatants was deter-
mined using a protein assay kit (Bio-Rad Laboratories). Equal
amounts of protein (30 µ g) were subjected to 10% SDS-PAGE and
the protein was then electrophoretically transferred to nitrocellu-602 Y Li and P Heldin 
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lose membranes. Non-specific binding sites on membranes were
blocked overnight at 4˚C with 5% defatted milk in Tris-buffered
saline (TBS; 20 mM Tris/HCl, 137 mM NaCl, pH 7.6) supple-
mented with 0.1% Tween 20. The membranes were then probed
either with a mAb against Hermes-3 (10 µ gm l –1), or with mAbs
against p21, cyclin A, cyclin B and Cdc2 p34 (2  µ gm l –1) for 3 h at
room temperature. After three washes with TBS-Tween, the
membranes were incubated with horseradish peroxidase-conjugated
anti-mouse IgG for 1 h, and immunocomplexes detected by
enhanced chemiluminescence (Amersham, Corp) according to the
manufacturer’s instructions. The blots were quantified using a
scanner and associated software (Molecular analyst, BioRad). 
Chemotaxis assays 
The migration capacities of mock-and HAS2-transfected cells
were assayed in a Boyden chamber. Subconfluent cultures were
harvested, resuspended in PBS containing 0.25% BSA and the cell
number was adjusted to 2 × 105 cells ml–1. Then the wells in the
upper compartment were loaded with 50 µ l of the cell suspension;
chemoattractant in the lower chamber, Ham’s F-10 medium
containing 1% FCS was added. In another experiment, cells were
added to the wells in the upper chamber, and as chemoattractant,
hyaluronan of a molecular weight of 3.9 × 106 was used at different
concentrations. The 2 chambers were separated by a 8 µ m thick
polycarbonate filter with 8 µ m pores (Corning Costar,
Netherlands), precoated overnight with a mixture of 100 µ gm l –1
vitrogen and 2 µ gm l –1 fibronectin solution in PBS at 4˚C. The
migration assays were run for 4.5 h at 37˚C in a humidified atmos-
phere of 5% CO2. At the end of the assay, the filters were removed,
fixed in ice-cold methanol, stained with Giemsa stain solution and
the cells on the upper side of the filter removed by scraping with a
cotton swab. The filters were then mounted between glass slide
and coverslip with Mountex. The number of cells per well that had
migrated through pores to the lower side of the filter were deter-
mined by counting the stained cells under a light microscope at a
magnification of 480x. For each set of experiments, the migration
capacity of mock-transfected cells toward 1% FCS or toward PBS
containing 0.25% BSA was used as a control and was referred to
as 100% migration. All experiments were performed in triplicates
and repeated 3 times. 
Hyaluronan-binding assay 
The binding assay using [3H]hyaluronan was performed essen-
tially as described by Asplund and Heldin (Asplund and Heldin,
1994). Briefly, subconfluent cultures of mock-and HAS2-trans-
fected cells were cultured overnight in F-10 medium containing
0.1% FCS (starvation medium) to remove traces of serum-derived
hyaluronan. However, in order to ensure that the hyaluronan-
binding sites were not occupied by endogenously synthesized
hyaluronan, the cell cultures were also treated with testicular
hyaluronidase. Following harvesting, the cells were aliquoted (5 ×
105 cells tube) in duplicate into BSA-precoated Eppendorf tubes
and various concentrations of [3H]hyaluronan, in the absence or
presence of nonlabelled hyaluronan (100  µ gm l –1; Mr 1.2 × 106),
were added and the cells were incubated for 60 min at room
temperature with gentle shaking. Following washing with PBS-D
the cultures were solubilized in 0.3 M NaOH-1% SDS (w/v) for 30
min at room temperature. After neutralization with 2 M HCl, the
suspension was mixed with scintillation cocktail (Ready Safe;
Beckman) and subjected to scintillation counting. Specific binding
was determined by subtraction of nonspecific binding (label
retained after the addition of nonlabelled hyaluronan). 
Statistics 
All statistical comparisons were made using paired Student’s 
t-test. All statistic calculations were performed with Stat View 4.01.
RESULTS 
Synthesis of hyaluronan by HAS2-transfected Mero-25
cells 
In order to investigate whether hyaluronan production affects the
malignant phenotype of mesotheliomas, Mero-25 cells were stably
transfected with cDNA for HAS2. After selection with G418, 15 of
the drug-resistant clones were isolated and established as stable
cell lines. The expression of HAS2 in transfected cell clones was
examined indirectly by quantification of hyaluronan content in
conditioned media. Among the G418 resistant clones, 3 clones
exhibiting hyaluronan synthesizing capacity were choosen for
further experiments. The 3 clones, designated M25-13, M25-15 and
M25-03, synthesized about 300 ng, 520 ng and 840 ng hyaluronan
per 5 × 104 cells and 24 h, respectively. A mock-transfected Mero-
25 cell clone which produced only minute amounts of hyaluronan,
was designated MV-01 and used as a control (Table 1). 
The size of hyaluronan chains synthesized de novo by M25-03,
the transfectants producing the highest amount of hyaluronan, was
determined by gel chromatography (Figure 1). The labelled
hyaluronan synthesized by M25-03 cells eluted in the void volume
of a Sephacryl column corresponding to a size larger than 3.9 ×
106. A second peak of an average molecular weight of 4 × 104 was
insensitive to Streptomyces hyaluronidase treatment and was there-
fore considered to represent other glycosaminoglycans. Both
mock- and HAS2-transfectants synthesized similar amounts of
non-hyaluronan glycosaminoglycans (Figure 1). The other 2 trans-
fectants, M25-13 and M25-15, also synthesized large hyaluronan
chains (data not shown). The size of hyaluronan synthesized by
normal mesothelial cells was also studied and found to be of high
molecular mass (data not shown). 
Overexpression of HAS2 gene affects cell morphology
and size of pericellular coats 
Untransfected or mock-transfected Mero-25 mesothelioma cells
exhibit an epithelial-like phenotype. After transfection with cDNA
for HAS2, a morphological conversion was observed; HAS2-
transfectants exhibited a more fibroblastic morphology than mock-
transfected cells which retained their epithelial character (Figure
2). This epitheloid morphology of mock-transfectants was not
altered even if the cells were cocultured with exogenous
hyaluronan (4 µ gm l –1) in a mechanically induced wounding
experiment in vitro (Brinck and Heldin, 1997; data not shown).
The fibroblastic morphology of HAS2-transfected cells was more
apparent at subconfluence than at confluence (data not shown). 
Our previous studies revealed that mesothelial cells produce
large amounts of hyaluronan and are surrounded by hyaluronan
containing coats. In contrast, mesothelioma cells only produce
minute amounts of hyaluronan and do not form coats (Heldin et al,
1995). We therefore investigated whether HAS2-transfectants couldHyaluronan-producing mesothelioma and tumour spreading 603
British Journal of Cancer (2001) 85(4), 600–607 © 2001 Cancer Research Campaign
form pericellular matrices. Mock-transfected cells did not form visible
coats, whereas 3 clones with different hyaluronan synthesizing
capacity were able to form coats. The size of the coats around HAS2-
transfectants correlated well to the amounts of hyaluronan released
into the medium from the individual transfectants (Table 1, Figure 2).
These results indicate that the expression of HAS2 gene and subse-
quent synthesis of hyaluronan by mesotheliomas affect the cell shape
and the organization of pericellular matrix, and thus the cellular func-
tions, most likely through other mechanisms than the hyaluronan
produced by neighbouring fibroblasts or mesothelial cells. 
Overproduction of hyaluronan makes cells more
anchorage independent 
We investigated the ability of mock- and HAS2-transfectants to
proliferate in the absence of attachment to a solid substrate by
using the soft agar assay; such anchorage-independent growth
correlates well with the transformed phenotype in vivo (Freedman
and Shin, 1974). The hyaluronan producing clones formed larger
colonies in soft agar than mock-transfected cells (Figure 3). The
area of colonies formed by the low (M25-13) and medium (M25-
15) hyaluronan producing clones were about 2-fold higher than the
mock-transfected cells (Figure 3B); an about 3-fold increase was
detected in the high hyaluronan producing clone, M25-03.
Furthermore, the number of the colonies was well correlated to the
amounts of hyaluronan synthesized by HAS2-transfectants (data
not shown). Moreover, the shape of the colonies formed by HAS2-
transfected cells was more irregular than the untransfected cells
(Figure 3A). These results suggest that increased hyaluronan
production may enhance mesothelioma cell tumorigenicity. 
Differencies in the proliferative capacity between mock- and
HAS2-transfectants were investigated by calculating the cell number
at different times after subculture. HAS2-transfected mesothelioma
cells exhibited about a 2-fold higher proliferative capacity than
mock-transfected cells (data not shown). The overexpression-
induced enhancement of cell proliferation prompted us to investigate
the expression levels of proteins involved in regulation of the cell
cycle. We analysed cell cycle regulatory proteins by Western blot of
asynchronously growing cells (Figure 4). The analysis revealed no
significant changes in p21 and Cdc2 p34 expression but an up-
regulation of the expression of cyclins A and B by the HAS2-
transfectants. The increases of cyclins A and B may be related to the
higher proliferative rate of hyaluronan-producing mesothelioma cells.
To assess further that HAS2-transfected mesothelioma cells prolif-
erate more rapidly than mock-transfected cells, we analysed the cell
cycle profiles of the hyaluronan producing clone M25-15 and mock-
transfected clone MV-01 synchronized by serum-starvation using
flow cytometry. 24 hours after release from quiencence by serum-
stimulation, both the nonhyaluronan-producing and hyaluronan-
producing clones began to move from the G1 phase to S and G2/M
phase in a similar manner (data not shown). However, as shown in
Figure 5, by 48 h after serum stimulation, HAS2-transfected cells had
a higher proportion of cells in S phase (26.6%) compared to mock-
transfected cells (18.9%) consistent with their faster proliferation. 
Overexpression of HAS2 induce cell motility and CD44
expression 
We also examined if hyaluronan overproduction affected the
migration of mesothelioma cells. The HAS2-transfected cells
placed in the upper compartment of a Boyden chamber and exposed
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Figure 1 Gel chromatography on a Sephacryl-HR column of
glycosaminoglycans synthesized by HAS2 transfected mesothelioma cells.
Mock (MV-01)- and HAS2 (M25-03)-transfected mesothelioma cells were
labelled with [3H]glucosamine for 24 h, and synthesized hyaluronan and 
other glycosaminoglycans were analysed on a Sephacryl-HR column 
(100 × 1 cm) as described in Materials and Methods. Closed and open
circles represent untreated and Streptomyces hyaluronidase treated material,
respectively. The peaks sensitive to hyaluronidase degradation represent
newly synthesized hyaluronan. The elution positions of hyaluronan molecular
weight markers are indicated by arrows 
Table 1 Hyaluronan production and pericellular coat forming capacity of
mock- and Has2-transfectants 
Transfectants Hyaluronan production  Area excluding 
(ng/5 × 104 cells/24 h) erythrocytes
Cell area 
MV-01 28 ± 2 1.00 ± 0.0 
M25-13 298 ± 12 2.10 ± 0.2a
M25-15 519 ± 59 2.62 ± 0.5a
M25-03 836 ± 9 2.97 ± 0.5a
Hyaluronan accumulation in 24 h conditioned media was estimated by using
a commercial kit; each value represents the average of duplicates ± range.
Cells (5 × 104 per 35 mm culture dish) were subjected to morphometric
analysis after 24 h of culture in complete medium as described in Materials
and Methods. The ratio between the area excluding erythrocytes and cell
area are the mean values of 20 randomly choosen cells ± SEM. 
aCompared to MV-01, P < 0.05. 604 Y Li and P Heldin 
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to 1% FCS exhibited higher migratory rates compared to that of
mock-transfected cells (Figure 6A). The M25-15 and M25-03 cells
which synthesize about 520 ng and 840 ng hyaluronan per 5 × 104
cells and day respectively, migrated through the filter about 2-fold
faster than the control MV-01 cells (Figure 6A). 
Since HAS2-transfected mesothelioma cells produced
hyaluronan of high molecular mass (more than 3.9 × 106 dalton), we
also investigated if hyaluronan of a molecular weight of 3.9 × 106
affected the migration ability of mock-transfected mesothelioma
Figure 2 HAS2 transfection induces morphological changes of mesothelioma cells and leads to formation of pericellular coats. Phase-contrast photographs 
of mock-transfected mesothelioma cells (MV-01) and HAS2-transfected mesothelioma clones producing different amounts of hyaluronan (M25-13, M25-15, 
M25-03), demonstrate that the HAS2-transfected cells exhibit a fibroblastic phenotype. In contrast, mock-transfected cells show an epithelial-like phenotype.
Cells (2 × 104 cells/35 mm dish) were cultured overnight in complete medium, then formalin fixed erythrocytes were added and the pericellular matrices were
visualized, as described in Materials and Methods. Phase-contrast photographs of the clones demonstrate the effects of overproduction of hyaluronan on coat
formation. A magnification of 600x is shown 
Figure 3 Hyaluronan overproduction promotes soft agar colony formation.
Phase contrast photographs (A) and area of colonies (B) of mock- and
HAS2-transfected cells grown in soft agar, as described in Materials and
Methods, are shown. The area of colonies larger than 0.5 arbitary units was
calculated in 10 randomly selected fields/well using NIH image program;
bars, SEM. The data shown are representative of 3 separate experiments 
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Figure 4 Expression of p21, cyclin A, cyclin B and Cdc2 p34 in mock- 
and HAS2-transfected mesothelioma cells. Cell lysates (30 µ g) from non-
synchronized mock (MV-01)- and HAS2-transfectants (M25-13, M25-15,
M25-03) were subjected to 10% SDS-PAGE, blotted onto nitrocellulose
membrane, and probed with 2 µ g ml–1 of monoclonal antibodies against p21,
cyclin A, cyclin B and Cdc2 p34. The data shown are representative of 3
different experiments 
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scells. As shown in Figure 6B, hyaluronan used as attractant in the
lower compartment of the chamber stimulated in a dose-dependent
manner the motility of MV-01 cells; a 2-fold increase in the migra-
tion was observed already at 10µ g ml–1 hyaluronan. The motile
response did not increase considerably at higher hyaluronan
concentrations. 
CD44 is a ubiquitous multifunctional cell surface molecule
which is the principle receptor for hyaluronan and is implicated in
cell–cell and cell–extracellular matrix interactions, cell migration
and lymph node homing (Naot et al, 1997; Knudson, 1998).
Therefore, we investigated CD44 expression and hyaluronan
binding capacity. As shown in Figure 7A, hyaluronan producing
clones exhibited about a 2-fold higher expression of CD44 mole-
cules compared to that of MV-01 control cells. Only the CD44
variant with a molecular mass of about 90 kDa was expressed.
Furthermore, we investigated whether this induction of CD44
molecules was associated with a comparable increase in specific
hyaluronan binding sites on the cell surface of M25-15 clone
(Figure 7B). The M25-15 cells exhibited about a 2-fold more
specific binding sites for [3H]hyaluronan than the MV-01 cells.
Interestingly, the degree of the increased CD44 expression and
hyaluronan-binding capacity correlated well with the production
of hyaluronan by the cell clones tested. 
DISCUSSION 
Malignant mesothelioma is histologically classified into 3 main
variants: epitheloid, fibrous and biphasic. Clinically, the epitheloid
histotype is the least aggressive, followed by biphasic, and by the
fibrous histotype which is the most aggressive. Each histotype
produces different extracellular matrix which affects their migra-
tion and spread (Roggli et al, 1992). About 20% of epithelial
mesotheliomas synthesize hyaluronan (Roggli et al, 1992) and up
to 70% of malignant pleura mesothelioma cases are associated
with elevated levels of hyaluronan in the pleura fluid and serum
(Thylen et al, 1999). In patients with hyaluronan-producing
mesotheliomas, a direct correlation was found between increasing
hyaluronan levels in the circulation and tumour burden (Dahl et al,
1989; Thylen et al, 1999). Interestingly, patients responding to
theurapeutic treatment exhibited decreased levels of hyaluronan in
serum. However, it is hard to make firm statements concerning the
relation between hyaluronan-producing mesotheliomas and their
clinical aggressiveness due to the limited numbers of patients
studied. In this study we have compared the biological properties
of the nonhyaluronan-producing mesothelioma cell line Mero-25,
with those of the same cells made to produce hyaluronan by trans-
fection of HAS2 cDNA. Increased synthesis of hyaluronan was
found to lead to an increased proliferation rate and to anchorage-
independent growth in soft agar. The pronounced differencies in
the size of colonies formed in soft agar between mock- and HAS2-
transfectants indicate an increased malignant phenotype of the
hyaluronan-producing mesotheliomas. Attempts to produce tumours
after subcutaneous injection of mock- and HAS2-transfectants in
nude mice failed (data not shown). This is consistent with previous
observations that different mesotheliomas did not produce tumours
either injected subcutaneously or intraperitoneally in these animals
(Versnel et al, 1989). It is notable, however, that the tumorigenicity of
mammary carcinoma and fibrosarcoma cells correlated with their
production of hyaluronan (Itano et al, 1999a; Kosaki et al, 1999). 
Previous studies suggested that hyaluronan synthesis occurs
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during cell division, and probably facilitate transient cell detach-
ment which occurs during mitosis (Brecht et al, 1986). The control
mechanism regulating eukaryotic M-phase onset are thought to be
triggered by oscillations in the activity of Cdc2 p34 which requires
various forms of cyclins; Cdc2 p34-cyclin B plays a critical role in
the G2 to M transition whereas Cdc2 p34-cyclin A functions in the
S phase (Nurse, 1990). Cell cycle analysis of hyaluronan synthe-
sizing mesothelioma cells revealed a shorter G1 phase and an
increase in both S and G2/M compared to nonhyaluronan-
producing mesothelioma cells (Figure 5), suggesting that expres-
sion of HAS2 gene and protein is associated with the induction of
the proliferation markers cyclin A and cyclin B (Figure 4).
Furthermore, the visualization of the hyaluronan-containing peri-
cellular matrices around hyaluronan-producing mesothelioma
cells may cause the displacement of cellular adhesions molecules
thereby facilitating cell detachment and progression through the
cell cycle. 
During the last few years several studies revealed that CD44-
hyaluronan interactions promote invasion and/or metastasis both in
vitro and in vivo (Thomas et al, 1992; Naot et al, 1997; Yu et al,
1997; Knudson, 1998). The mechanism proposed to explain how
hyaluronan facilitates cell migration is based on its intrinsic
physicochemical properties to get hydrated and subsequently
induce tissue expansion. The direct tumour cell–hyaluronan inter-
actions mediated through CD44 molecules may play an important
role in facilitating haptotactic migration through the tumour-
associated hyaluronan-rich matrix. The increase in the expression
of CD44 molecules (Figure 7) and the increased migratory ability
of HAS2 transfectants (Figure 6), suggests that hyaluronan
production by mesothelioma correlates with local invasive behav-
iour. It is of importance to point out here that cell lines and early-
passage mesothelioma cells, but not normal mesothelial cells,
express functionally active CD44 hyaluronan receptors (Asplund
and Heldin, 1994; Teder et al, 1996). The functional CD44 mole-
cules on mesothelioma could result in an enhanced motility of
tumour cells along areas reach in hyaluronan. The molecular
mechanisms that control the gene expression of the three HAS
isoforms and their significance in terms of the function of
hyaluronan synthesized has not been fully elucidated so far.
According to our and other laboratories observations (Brinck and
Heldin, 1999; Itano et al, 1999b) each HAS isoform exhibit intrinsic
differencies both in their expression pattern and in the amount and
size of the synthesized polymer. A more recent report revealed that
the HAS2 isoform was induced during the healing of a mechanical
injury of mesothelial cell cultures and that hyaluronan synthesis
was located at the leading edge of the wound and promoted cell
migration (Yung et al, 2000). However, concerning the role of
hyaluronan in cell migration, further studies by us (Brinck and
Heldin, 1999) and other laboratories (Forrester and Wilkinson,
1981) revealed an inverse correlation between cell migration and
hyaluronan levels surrounding the cells. It should be emphasized,
however, that other cell types were investigated. In addition, the
HAS3 isoform, and not the HAS2 isoform, was overexpressed
(Brinck and Heldin, 1999). Taken together, most likely hyaluronan
synthesized by each one of the 3 HAS isoforms affects cell migra-
tion in a manner which is dependent on polymer size, concentra-
tion and cell target type. Immunohistochemical studies of
malignant mesotheliomas producing or not producing hyaluronan
revealed that hyaluronan production correlated to the expression of
different antigens most likely indicating a more anaplastic tumour
(Thylén et al, 1997). An elucidation of the mechanisms involved in
the induction of hyaluronan synthesis by mesotheliomas will
increase our understanding of the parameters which influence local
spreading of malignant mesothelioma. Such knowledge will be
important when considering future therapeutic strategies of
mesothelioma. 
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